PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28511060-0 2017 A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin. Cisplatin 57-66 ribonuclease pancreatic Bos taurus 22-29 28511060-2 2017 A dimer, a trimer and higher oligomers of bovine pancreatic ribonuclease (RNase A) obtained upon reaction with CDDP in 1:10 protein to metal ratio at 37 C have been previously characterized. Cisplatin 111-115 ribonuclease pancreatic Bos taurus 74-81 28511060-10 2017 Although platinated oligomers of RNase A formed upon reaction with CDDP, carboplatin and oxaliplatin retain a residual ribonuclease activity, they do not show cytotoxic action, suggesting that protein aggregation processes induced by Pt-based drugs can represent a collateral drawback, which affects the functional state of protein targets and reduces the efficacy of Pt-based drug treatment. Cisplatin 67-71 ribonuclease pancreatic Bos taurus 33-40 26239545-2 2015 Here, the X-ray structures of the adducts formed upon reaction of carboplatin and oxaliplatin with bovine pancreatic ribonuclease (RNase A) are reported and compared with results obtained for the structure of the RNase A-cisplatin adduct derived from isomorphous crystals, under the same experimental conditions. Cisplatin 221-230 ribonuclease pancreatic Bos taurus 131-138 25756333-1 2015 The reaction between cis-diamminedichloroplatinum(II) (CDDP), cisplatin, a common anticancer drug, and bovine pancreatic ribonuclease (RNase A), induces extensive protein aggregation, leading to the formation of one dimer, one trimer and higher oligomers whose yields depend on cisplatin/protein ratio. Cisplatin 21-53 ribonuclease pancreatic Bos taurus 135-142 25756333-1 2015 The reaction between cis-diamminedichloroplatinum(II) (CDDP), cisplatin, a common anticancer drug, and bovine pancreatic ribonuclease (RNase A), induces extensive protein aggregation, leading to the formation of one dimer, one trimer and higher oligomers whose yields depend on cisplatin/protein ratio. Cisplatin 55-59 ribonuclease pancreatic Bos taurus 135-142 25756333-1 2015 The reaction between cis-diamminedichloroplatinum(II) (CDDP), cisplatin, a common anticancer drug, and bovine pancreatic ribonuclease (RNase A), induces extensive protein aggregation, leading to the formation of one dimer, one trimer and higher oligomers whose yields depend on cisplatin/protein ratio. Cisplatin 62-71 ribonuclease pancreatic Bos taurus 135-142 25756333-1 2015 The reaction between cis-diamminedichloroplatinum(II) (CDDP), cisplatin, a common anticancer drug, and bovine pancreatic ribonuclease (RNase A), induces extensive protein aggregation, leading to the formation of one dimer, one trimer and higher oligomers whose yields depend on cisplatin/protein ratio. Cisplatin 278-287 ribonuclease pancreatic Bos taurus 135-142